story of the week
Neoadjuvant Atezolizumab Plus Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy vs Placebo and Chemotherapy for Early-Stage Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Atezolizumab in Combination With Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy Versus Placebo and Chemotherapy in Patients With Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Randomised, Double-Blind, Phase 3 Trial
Lancet 2020 Sep 18;[EPub Ahead of Print], EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung, R Hegg, A Koehler, J Sohn, H Iwata, ML Telli, C Ferrario, K Punie, F Penault-Llorca, S Patel, AN Duc, M Liste-Hermoso, V Maiya, L Molinero, SY Chui, N HarbeckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.